Design and Simulation of an AI ‐Powered Artificial Pancreas System With Personalized Glucose Sensing and Insulin Delivery

BACKGROUND: Achieving tight glycemic control in Type 1 diabetes is challenged by non-linear metabolic dynamics and insulin-stacking risk. Artificial intelligence models offer improved personalization, but their opacity raises safety concerns, particularly for basal insulin dosing, which is often treated as static in existing decision-support systems. METHODS: We propose a hybrid closed-loop system combining a data-driven LightGBM regressor for basal dose prediction, trained on the T1D-UOM dataset, with a physiologically grounded, rule-based safety layer at the edge. Basal insulin is predicted from cyclical time encoding and glucose rate-of-change; bolus dosing follows carbohydrate intake and correction requirements. A time-bounded insulin-on-board model, an uncertainty-adaptive post-bolus damping factor, and a predictive low-glucose-suspend rule reproducing the Tandem Basal-IQ protocol together suspend or reduce delivery when residual insulin is high or hypoglycemia is projected. The system was evaluated in silico over 60 continuous days under shadow-mode replay and closed-loop reduced-order simulation, including an ablation with bolus delivery suppressed. RESULTS: U). The hybrid controller maintained Time-in-Range at 62.8% within the reduced-order closed-loop simulation, with no violations of the insulin-on-board suspension or damping rules; suppressing bolus delivery in an ablation within this simulation dropped Time-in-Range to 26.1%, indicating that, within the reduced-order model, bolus delivery is a determinant of simulated glycemic outcome. CONCLUSIONS: The proposed architecture demonstrates a safety-audited template for combining machine-learning basal prediction with clinically grounded dosing rules. Validation on real outcome data and physical hardware is identified as the next steps toward clinical translation.

Authors

Publication Details

Journal
Artificial Organs
Published
2026-11-13
DOI
https://doi.org/10.1111/aor.70278
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Design and Simulation of an AI ‐Powered Artificial Pancreas System With Personalized Glucose Sensing and Insulin Delivery

Jasti Sateesh, Turimerla Pratap, G. Kalyani
Artificial Organs
Diabetes Management and Research
article

Design and Simulation of an AI ‐Powered Artificial Pancreas System With Personalized Glucose Sensing and Insulin Delivery

Jasti Sateesh, Turimerla Pratap, G. Kalyani
article en

Abstract

BACKGROUND: Achieving tight glycemic control in Type 1 diabetes is challenged by non-linear metabolic dynamics and insulin-stacking risk. Artificial intelligence models offer improved personalization, but their opacity raises safety concerns, particularly for basal insulin dosing, which is often treated as static in existing decision-support systems. METHODS: We propose a hybrid closed-loop system combining a data-driven LightGBM regressor for basal dose prediction, trained on the T1D-UOM dataset, with a physiologically grounded, rule-based safety layer at the edge. Basal insulin is predicted from cyclical time encoding and glucose rate-of-change; bolus dosing follows carbohydrate intake and correction requirements. A time-bounded insulin-on-board model, an uncertainty-adaptive post-bolus damping factor, and a predictive low-glucose-suspend rule reproducing the Tandem Basal-IQ protocol together suspend or reduce delivery when residual insulin is high or hypoglycemia is projected. The system was evaluated in silico over 60 continuous days under shadow-mode replay and closed-loop reduced-order simulation, including an ablation with bolus delivery suppressed. RESULTS: U). The hybrid controller maintained Time-in-Range at 62.8% within the reduced-order closed-loop simulation, with no violations of the insulin-on-board suspension or damping rules; suppressing bolus delivery in an ablation within this simulation dropped Time-in-Range to 26.1%, indicating that, within the reduced-order model, bolus delivery is a determinant of simulated glycemic outcome. CONCLUSIONS: The proposed architecture demonstrates a safety-audited template for combining machine-learning basal prediction with clinically grounded dosing rules. Validation on real outcome data and physical hardware is identified as the next steps toward clinical translation.

Artificial Organs
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon